DUBLIN--(BUSINESS WIRE)--Horizon Pharma plc (NASDAQ: HZNP) announced its second-quarter 2018 financial results today. Effective with the second quarter of 2018, the Company has realigned its operating structure and is reporting financial results as two separate segments: the orphan and rheumatology segment, its strategic growth business, and the primary care segment. The new operating structure reflects the evolution of the Company’s strategy and vision of transitioning Horizon Pharma to a biopharmaceutical company focused on rare disease medicines.
“Our orphan and rheumatology segment generated record quarterly net sales, driven by accelerating KRYSTEXXA growth, reflecting the additional investments we are making this year,” said Timothy P. Walbert, chairman, president and chief executive officer, Horizon Pharma plc. “Our clinical programs continue to advance, with target enrollment now complete in the teprotumumab Phase 3 trial, well ahead of schedule. Additionally, we plan on initiating a new study of KRYSTEXXA to continue exploring a broader clinical profile of this medicine, the only FDA-approved treatment for uncontrolled gout. These advancements support our transformation into a rare disease medicine focused company with a robust pipeline enabling sustainable growth.”
|
|
|||||||||||||||||||||||||||
| Financial Highlights | |||||||||||||||||||||||||||
| % | % | ||||||||||||||||||||||||||
| (in millions except for per share amounts and percentages) | Q2 18 | Q2 17 | Change | YTD 18 | YTD 17 | Change | |||||||||||||||||||||
| Net sales | $ | 302.8 | $ | 289.5 | 5 | $ | 526.7 | $ | 510.4 | 3 | |||||||||||||||||
| Net loss | (32.8 | ) | (209.5 | ) | 84 | (190.2 | ) | (300.1 | ) | 37 | |||||||||||||||||
| Non-GAAP net income | 80.5 | 68.3 | 18 | 85.3 | 103.3 | (17 | ) | ||||||||||||||||||||
| Adjusted EBITDA | 116.8 | 127.0 | (8 | ) | 150.4 | 178.9 | (16 | ) | |||||||||||||||||||
| Net loss per share - diluted | $ | (0.20 | ) | $ | (1.29 | ) | 84 | $ | (1.15 | ) | $ | (1.85 | ) | 38 | |||||||||||||
| Non-GAAP earnings per share - diluted | 0.48 | 0.41 | 17 | 0.51 | 0.63 | (19 | ) | ||||||||||||||||||||
Second-Quarter and Recent Company Highlights
-
Teprotumumab: OPTIC, the teprotumumab Phase 3 clinical trial,
has reached its target enrollment of 76 patients, significantly ahead
of schedule. The remaining few subjects in screening will be allowed
to randomize over the next several weeks.
Teprotumumab is a fully human monoclonal antibody IGF-1R inhibitor being developed for the treatment of thyroid eye disease (TED), in which the muscles and fatty tissue behind the eye become inflamed, which can lead to proptosis, or bulging of the eye, and diplopia, or double vision, as well as quality-of-life issues. In October, data will be presented at the 2018 American Thyroid Association (ATA) meeting from the follow-up period of the Phase 2 clinical trial, during which the Company continued to collect data on study patients off therapy out to 48 weeks to assess durability of response. - New KRYSTEXXA Immunomodulation Study: The Company is planning on initiating a new study of KRYSTEXXA to continue to explore a broader clinical profile of this medicine, the only FDA-approved treatment for uncontrolled gout (chronic gout that is refractory to conventional therapies). The study will evaluate the impact of adding methotrexate to KRYSTEXXA to enhance the patient response rate. Methotrexate is the most common immunomodulator used by rheumatologists. Enrollment is expected to begin in the fourth quarter of 2018.
- New Uncontrolled Gout and KRYSTEXXA Data Presented at EULAR: In June, the Company participated in the 2018 Annual European Congress of Rheumatology (EULAR) in Amsterdam, where new insights on both gout and KRYSTEXXA were presented. One presentation highlighted a 27 percent increase in U.S. emergency department visits between 2006 and 2014 for people living with gout, suggesting a sizeable and growing population of gout patients who are uncontrolled and not well managed. Several KRYSTEXXA data analyses underscored the complex nature of uncontrolled gout, the potential systemic effects of elevated serum uric acid (sUA) levels and the need to manage uncontrolled gout aggressively. These presentations support the Company’s continued efforts to increase awareness and understanding of uncontrolled gout and the benefits of KRYSTEXXA.
- R&D Leadership: The Company made several important leadership additions to its research and development (R&D) organization to expand its capabilities, partner with the business development team in identifying and evaluating development-stage opportunities and lead the orphan and rheumatology therapeutic areas’ clinical development strategies.
- Intellectual Property Update: The Company received two new patents from the U.S. Patent and Trademark Office during the quarter that cover RAVICTI®, with two additional patents scheduled to be issued in August, resulting in five new patents in an 18-month period. In addition, the Company settled litigation in June with Lupin relating to RAVICTI. Lupin’s license to enter the market with a generic version of RAVICTI would begin on July 1, 2026.
- Best Workplace Awards: Great Place to Work® and FORTUNE Magazine selected Horizon Pharma as the Number One place to work on FORTUNE’s "Best Workplaces in Health Care & Biopharma" list. The Company has also been awarded a 2018 “Best Places to Work in Chicago” designation by Crain’s Chicago Business, as well as named to its “10 Best Places to Work for Women” list. In addition, in July, the Company was recognized by PEOPLE and Great Place to Work® as one of the 2018 “50 Companies That Care,” a list that spotlights companies with 1,000 or more employees that have succeeded in business while also demonstrating respect, compassion and concern for their communities, their employees and the environment.
Research and Development Programs
Orphan Candidates and Programs:
- Teprotumumab: Teprotumumab is the Company’s fully human monoclonal antibody IGF-1R inhibitor in development for the treatment of TED. The pivotal Phase 3 confirmatory study is evaluating teprotumumab for the treatment of moderate-to-severe active TED, which has no FDA-approved treatments. The Company estimates peak annual U.S. net sales of more than $750 million for teprotumumab, assuming FDA approval.
Rheumatology Pipeline Candidates and Programs:
-
KRYSTEXXA Immunomodulation Studies: The evaluation of the use
of immunomodulation therapies to enhance the response rate to
KRYSTEXXA is being studied in two investigator-initiated trials, as
well as a new trial being initiated by the Company. The three trials
are evaluating different immunomodulators, all of which are used by
rheumatologists.
- Methotrexate to Increase Response Rates in Patients with Uncontrolled GOut Receiving KRYSTEXXA (MIRROR): a Horizon Pharma-sponsored multicenter, efficacy and safety study for methotrexate co-administered with KRYSTEXXA to evaluate the impact of methotrexate weekly for one month prior to dosing with KRYSTEXXA and then throughout the 24 weeks of treatment with KRYSTEXXA. Enrollment is expected to begin in the fourth quarter of 2018.
- REduCing Immunogenicity to PegloticasE (RECIPE): a double-blind, placebo-controlled trial for mycophenolate mofetil (MMF) co-administered with KRYSTEXXA to evaluate the impact of MMF daily for two weeks prior to dosing with KRYSTEXXA, followed by a 12-week course of KRYSTEXXA every two weeks along with daily doses of MMF, followed by dosing of KRYSTEXXA alone every two weeks for 12 weeks.
- Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect (TRIPLE) is an exploratory, open-label adaptive trial with multiple patient cohorts, including one evaluating the impact of adding daily doses of azathioprine for a two-week run-in period, followed by KRYSTEXXA every two weeks for a total of 13 doses, along with daily doses of azathioprine.
- Next-generation Biologic Programs for Uncontrolled Gout: The Company is pursuing two development programs for next-generation biologics for uncontrolled gout, HZN-003 and PASylated uricase technology to support and sustain the Company’s market leadership in uncontrolled gout. The programs are exploring the use of optimized uricase technology as well as optimized PEGylation and PASylation technology.
Second-Quarter Financial Results
Note: For additional detail and reconciliation of non-GAAP financial measures to the most directly comparable GAAP financial measures, please refer to the tables at the end of this release.
- Net Sales: Second-quarter 2018 net sales were $302.8 million, an increase of 4.6 percent, driven by continued strong growth of the Company’s orphan and rheumatology medicines. Year-over-year growth would have been 6.3 percent, excluding second-quarter 2017 net sales of $4.5 million for PROCYSBI® and QUINSAIR™ in the Europe, the Middle East and Africa (EMEA) regions, which were divested on June 23, 2017.
- Gross Profit: Under U.S. GAAP in the second quarter of 2018, the gross profit ratio was 67.0 percent compared to 55.0 percent in the second quarter of 2017. The non-GAAP gross profit ratio in the second quarter of 2018 was 90.2 percent compared to 90.6 percent in the second quarter of 2017.
- Operating Expenses: R&D expenses were 8.0 percent of net sales and selling, general and administrative (SG&A) expenses were 58.3 percent of net sales. Non-GAAP R&D expenses were 6.7 percent of net sales, and non-GAAP SG&A expenses were 45.0 percent of net sales.
- Income Tax Rate: The income tax rate in the second quarter of 2018 on a GAAP basis was negative 13.7 percent and on a non-GAAP basis was 12.0 percent.
- Net (Loss) Income: On a GAAP basis in the second quarter of 2018, net loss was $32.8 million. Second-quarter 2018 non-GAAP net income was $80.5 million.
- Adjusted EBITDA: Second-quarter 2018 adjusted EBITDA was $116.8 million.
- Earnings (Loss) per Share: On a GAAP basis in the second quarter of 2018, diluted loss per share was $0.20; in the second quarter of 2017, diluted loss per share was $1.29. Non-GAAP diluted earnings per share in the second quarter of 2018 and 2017 were $0.48 and $0.41, respectively. Weighted average shares outstanding used for calculating GAAP diluted loss per share and non-GAAP diluted earnings per share in the second quarter of 2018 were 165.5 million and 169.4 million, respectively.
Second-Quarter Segment Results
The Company has realigned its structure to operate its strategic growth business, orphan and rheumatology, separately from its primary care business. The new structure allows the Company to more efficiently allocate its resources to address unmet treatment needs for patients with rare diseases. As a result of the realignment, effective with the second-quarter of 2018, the Company is reporting its financial results as two separate segments: the orphan and rheumatology segment and the primary care segment, reporting net sales and operating income for each segment. Historical segment net sales and operating income for 2017 are provided in the accompanying financial schedules.
Management uses net sales and segment operating income to evaluate the performance of the Company’s two segments. While segment operating income contains certain adjustments to the directly comparable GAAP figures in the Company’s consolidated financial results, it is considered to be prepared in accordance with GAAP for purposes of presenting the Company’s segment operating results.
|
Orphan and Rheumatology Segment |
|||||||||||||||||||
| % | % | ||||||||||||||||||
| (in millions except for percentages) | Q2 18 | Q2 17 | Change | YTD 18 | YTD 17 | Change | |||||||||||||
| RAVICTI® | 57.0 | 47.2 | 21 | 106.1 | 91.1 | 16 | |||||||||||||
| PROCYSBI®(1) | 38.4 | 36.7 | 5 | 73.4 | 71.0 | 3 | |||||||||||||
| ACTIMMUNE® | 27.4 | 28.8 | (5 | ) | 52.2 | 55.0 | (5 | ) | |||||||||||
| BUPHENYL® | 5.2 | 6.3 | (16 | ) | 11.0 | 12.6 | (12 | ) | |||||||||||
| QUINSAIRTM(1) | 0.1 | 1.4 | (93 | ) | 0.2 | 3.2 | (94 | ) | |||||||||||
| Orphan | $ | 128.1 | $ | 120.4 | 6 | $ | 242.9 | $ | 232.9 | 4 | |||||||||
| KRYSTEXXA® | 58.6 | 38.3 | 53 | 105.3 | 69.9 | 51 | |||||||||||||
| RAYOS® | 13.5 | 11.6 | 16 | 24.1 | 21.9 | 10 | |||||||||||||
| LODOTRA® | 1.5 | 1.8 | (15 | ) | 1.7 | 2.7 | (38 | ) | |||||||||||
| Rheumatology | $ | 73.6 | $ | 51.7 | 42 | $ | 131.1 | $ | 94.5 | 39 | |||||||||
| Orphan and Rheumatology Net Sales | $ | 201.7 | $ | 172.1 | 17 | $ | 374.0 | $ | 327.3 | 14 | |||||||||
| Orphan and Rheumatology Segment Operating Income | $ | 70.6 | $ | 64.7 | 9 | $ | 113.7 | $ | 114.4 | (1 | ) | ||||||||
|
(1) |
On June 23, 2017, Horizon Pharma completed the divestiture of a European subsidiary that owned the marketing rights to PROCYSBI and QUINSAIR in Europe, the Middle East and Africa (EMEA) to Chiesi Farmaceutici S.p.A. Horizon Pharma retains marketing rights for the two medicines in the United States, Canada, Latin America and Asia. Second-quarter and year-to-date 2017 net sales of PROCYSBI and QUINSAIR in EMEA were $4.5 million and $9.5 million, respectively. |
||||||||||||||||||
- Second-quarter 2018 net sales of the orphan and rheumatology segment were $201.7 million, an increase of 17.2 percent over the prior year’s quarter, driven by continued strong KRYSTEXXA growth, as well as growth of RAVICTI and PROCYSBI. Excluding the second-quarter 2017 EMEA net sales of $4.5 million for PROCYSBI and QUINSAIR that were divested in June 2017, orphan and rheumatology segment year-over-year net sales growth would have been 20.4 percent.
- In line with the Company’s expectations, second-quarter 2018 orphan and rheumatology segment operating income was $70.6 million, or 35 percent of orphan and rheumatology net sales. The Company is investing significantly in the commercial expansion of KRYSTEXXA in 2018, which is expected to continue to drive future net sales growth and margin expansion over time.
|
Primary Care Segment |
||||||||||||||||||||||||
| % | % | |||||||||||||||||||||||
| (in millions except for percentages) | Q2 18 | Q2 17 | Change | YTD 18 | YTD 17 | Change | ||||||||||||||||||
| PENNSAID® 2% | 47.6 | 51.2 | (7 | ) | 74.4 | 92.8 | (20 | ) | ||||||||||||||||
| DUEXIS® | 30.7 | 43.6 | (30 | ) | 46.4 | 61.3 | (24 | ) | ||||||||||||||||
| VIMOVO® | 21.9 | 21.1 | 3 | 30.2 | 26.0 | 16 | ||||||||||||||||||
| MIGERGOT® | 0.9 | 1.5 | (35 | ) | 1.7 | 2.9 | (41 | ) | ||||||||||||||||
| Primary Care Net Sales | $ | 101.1 | $ | 117.4 | (14 | ) | $ | 152.7 | $ | 183.0 | (17 | ) | ||||||||||||
| Primary Care Segment Operating Income | $ | 45.9 | $ | 62.4 | (26 | ) | $ | 36.3 | $ | 65.0 | (44 | ) | ||||||||||||
- Second-quarter 2018 net sales of the primary care segment were $101.1 million.
- In line with the Company’s expectations, second-quarter 2018 operating income for the primary care segment was $45.9 million, or 45 percent of primary care net sales.
Cash Flow Statement and Balance Sheet Highlights
- On a GAAP basis in the second quarter of 2018, operating cash flow was $61.8 million. Non-GAAP operating cash flow was $75.2 million.
- The Company had cash and cash equivalents of $710.2 million as of June 30, 2018.
- As of June 30, 2018, the total principal amount of debt outstanding was $1.993 billion, which consists of $818 million in senior secured term loans due 2024; $300 million senior notes due 2024; $475 million senior notes due 2023; and $400 million exchangeable senior notes due 2022. As of June 30, 2018, net debt was $1.283 billion.
Full-Year 2018 Guidance
The Company continues to expect full-year 2018 net sales in a range of $1.170 billion to $1.200 billion. The Company increased its full-year 2018 adjusted EBITDA guidance to a range of $400 million to $420 million, from $390 million to $415 million. The Company continues to project full-year 2018 net sales growth for KRYSTEXXA of more than 65 percent.
Webcast
At 8 a.m. EDT / 1 p.m. IST today, the Company will host a live webcast to review its financial and operating results and provide a general business update. The live webcast and a replay may be accessed at http://ir.horizon-pharma.com. Please connect to the Company's website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. A replay of the webcast will be available approximately two hours after the live webcast.
About Horizon Pharma plc
Horizon Pharma plc is focused on researching, developing and commercializing innovative medicines that address unmet treatment needs for rare and rheumatic diseases. By fostering a growing pipeline of medicines in development and exploring all potential uses for currently marketed medicines, we strive to make a powerful difference for patients, their caregivers and physicians. For us, it’s personal: by living up to our own potential, we are helping others live up to theirs. For more information, please visit www.horizonpharma.com, follow us @HZNPplc on Twitter or like us on Facebook.
Note Regarding Use of Non-GAAP Financial Measures
EBITDA, or earnings before interest, taxes, depreciation and amortization, and adjusted EBITDA are used and provided by Horizon Pharma as non-GAAP financial measures. Horizon Pharma provides certain other financial measures such as non-GAAP net income, non-GAAP diluted earnings per share, non-GAAP gross profit and gross profit ratio, non-GAAP operating expenses, non-GAAP operating income, non-GAAP tax rate, non-GAAP operating cash flow and net debt, each of which include adjustments to GAAP figures. These non-GAAP measures are intended to provide additional information on Horizon Pharma’s performance, operations, expenses, profitability and cash flows. Adjustments to Horizon Pharma's GAAP figures as well as EBITDA exclude acquisition and/or divestiture-related expenses, charges related to the discontinuation of ACTIMMUNE development for Friedreich’s ataxia, gain from divestiture, an upfront fee for a license of a patent, litigation settlements, loss on debt extinguishment, costs of debt refinancing, drug manufacturing harmonization costs, restructuring and realignment costs, as well as non-cash items such as share-based compensation, depreciation and amortization, royalty accretion, non-cash interest expense, long-lived asset impairment charges, impacts of contingent royalty liability remeasurements and other non-cash adjustments. Certain other special items or substantive events may also be included in the non-GAAP adjustments periodically when their magnitude is significant within the periods incurred. Horizon maintains an established non-GAAP cost policy that guides the determination of what costs will be excluded in non-GAAP measures. Horizon Pharma believes that these non-GAAP financial measures, when considered together with the GAAP figures, can enhance an overall understanding of Horizon Pharma's financial and operating performance. The non-GAAP financial measures are included with the intent of providing investors with a more complete understanding of the Company’s historical and expected 2018 financial results and trends and to facilitate comparisons between periods and with respect to projected information. In addition, these non-GAAP financial measures are among the indicators Horizon Pharma's management uses for planning and forecasting purposes and measuring the Company's performance. For example, adjusted EBITDA is used by Horizon Pharma as one measure of management performance under certain incentive compensation arrangements. These non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, non-GAAP financial measures used by other companies. Horizon Pharma has not provided a reconciliation of its full-year 2018 adjusted EBITDA outlook to an expected net income (loss) outlook because certain items such as acquisition/divestiture-related expenses and share-based compensation that are a component of net income (loss) cannot be reasonably projected due to the significant impact of changes in Horizon Pharma's stock price, the variability associated with the size or timing of acquisitions/divestitures and other factors. These components of net income (loss) could significantly impact Horizon Pharma’s actual net income (loss).
Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to Horizon Pharma's full-year 2018 net sales and adjusted EBITDA guidance, expected growth in net sales of certain medicines, estimated peak annual net sales of teprotumumab, if approved; expected financial performance in future periods; expected timing of clinical trials, including the Phase 3 clinical trial of teprotumumab; expected increases in investment in Horizon Pharma’s rare disease medicine pipeline and the impact thereof; potential market opportunity for Horizon Pharma’s medicines in approved and potential additional indications; and business and other statements that are not historical facts. These forward-looking statements are based on Horizon Pharma's current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks that Horizon Pharma’s actual future financial and operating results may differ from its expectations or goals; Horizon Pharma’s ability to grow net sales from existing products; the availability of coverage and adequate reimbursement and pricing from government and third-party payers; risks relating to Horizon Pharma’s ability to successfully implement its business strategies; risks inherent in developing novel medicine candidates, such as teprotumumab, and existing medicines for new indications; risks related to acquisition integration and achieving projected benefits; risks associated with regulatory approvals; risks in the ability to recruit, train and retain qualified personnel; competition, including potential generic competition; the ability to protect intellectual property and defend patents; regulatory obligations and oversight, including any changes in the legal and regulatory environment in which Horizon Pharma operates and those risks detailed from time-to-time under the caption "Risk Factors" and elsewhere in Horizon Pharma's filings and reports with the SEC. Horizon Pharma undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information.
| Horizon Pharma plc | ||||||||||||||||||||
| Condensed Consolidated Statements of Operations (Unaudited) | ||||||||||||||||||||
| (in thousands, except share and per share data) | ||||||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||||||
| 2018 | 2017 | 2018 | 2017 | |||||||||||||||||
| Net sales | $ | 302,835 | $ | 289,507 | $ | 526,716 | $ | 510,366 | ||||||||||||
| Cost of goods sold | 100,082 | 130,150 | 216,174 | 269,266 | ||||||||||||||||
| Gross profit | 202,753 | 159,357 | 310,542 | 241,100 | ||||||||||||||||
| OPERATING EXPENSES: | ||||||||||||||||||||
| Research and development | 24,265 | 163,101 | 41,910 | 176,162 | ||||||||||||||||
| Selling, general and administrative | 176,674 | 159,653 | 356,273 | 333,718 | ||||||||||||||||
| Impairment of long-lived assets | - | 22,270 | 37,853 | 22,270 | ||||||||||||||||
| Total operating expenses | 200,939 | 345,024 | 436,036 | 532,150 | ||||||||||||||||
| Operating income (loss) | 1,814 | (185,667 | ) | (125,494 | ) | (291,050 | ) | |||||||||||||
| OTHER EXPENSE, NET: | ||||||||||||||||||||
| Interest expense, net | (31,030 | ) | (31,608 | ) | (61,484 | ) | (63,591 | ) | ||||||||||||
| Foreign exchange (loss) gain | (5 | ) | 151 | (115 | ) | (108 | ) | |||||||||||||
| Gain on divestiture | - | 5,856 | - | 5,856 | ||||||||||||||||
| Loss on debt extinguishment | - | - | - | (533 | ) | |||||||||||||||
| Other income (expense), net | 347 | (35 | ) | 525 | - | |||||||||||||||
| Total other expense, net | (30,688 | ) | (25,636 | ) | (61,074 | ) | (58,376 | ) | ||||||||||||
| Loss before expense (benefit) for income taxes | (28,874 | ) | (211,303 | ) | (186,568 | ) | (349,426 | ) | ||||||||||||
| Expense (benefit) for income taxes | 3,962 | (1,767 | ) | 3,596 | (49,320 | ) | ||||||||||||||
| Net loss | $ | (32,836 | ) | $ | (209,536 | ) | $ | (190,164 | ) | $ | (300,106 | ) | ||||||||
| Net loss per ordinary share - basic and diluted | $ | (0.20 | ) | $ | (1.29 | ) | $ | (1.15 | ) | $ | (1.85 | ) | ||||||||
| Weighted average ordinary shares outstanding - basic and diluted | 165,536,826 | 162,931,930 | 164,921,722 | 162,486,946 | ||||||||||||||||
| Horizon Pharma plc | |||||||||||||
| Condensed Consolidated Balance Sheets (Unaudited) | |||||||||||||
| (in thousands, except share data) | |||||||||||||
| As of | |||||||||||||
| June 30, | December 31, | ||||||||||||
| 2018 | 2017 | ||||||||||||
| ASSETS | |||||||||||||
| CURRENT ASSETS: | |||||||||||||
| Cash and cash equivalents | $ | 710,211 | $ | 751,368 | |||||||||
| Restricted cash | 6,394 | 6,529 | |||||||||||
| Accounts receivable, net | 403,671 | 405,214 | |||||||||||
| Inventories, net | 50,105 | 61,655 | |||||||||||
| Prepaid expenses and other current assets | 64,231 | 43,402 | |||||||||||
| Total current assets | 1,234,612 | 1,268,168 | |||||||||||
| Property and equipment, net | 18,070 | 20,405 | |||||||||||
| Developed technology, net | 2,272,154 | 2,443,949 | |||||||||||
| Other intangible assets, net | 5,039 | 5,441 | |||||||||||
| Goodwill | 426,441 | 426,441 | |||||||||||
| Deferred tax assets, net | 4,185 | 3,470 | |||||||||||
| Other assets | 29,224 | 36,081 | |||||||||||
| Total assets | $ | 3,989,725 | $ | 4,203,955 | |||||||||
| LIABILITIES AND SHAREHOLDERS' EQUITY | |||||||||||||
| CURRENT LIABILITIES: | |||||||||||||
| Long-term debt—current portion | $ | - | $ | 10,625 | |||||||||
| Accounts payable | 31,110 | 34,681 | |||||||||||
| Accrued expenses | 173,619 | 175,697 | |||||||||||
| Accrued trade discounts and rebates | 449,683 | 501,753 | |||||||||||
| Accrued royalties—current portion | 65,604 | 65,328 | |||||||||||
| Deferred revenues—current portion | 5,629 | 6,885 | |||||||||||
| Total current liabilities | 725,645 | 794,969 | |||||||||||
| LONG-TERM LIABILITIES: | |||||||||||||
| Exchangeable notes, net | 323,105 | 314,384 | |||||||||||
| Long-term debt, net of current | 1,562,013 | 1,576,646 | |||||||||||
| Accrued royalties, net of current | 293,626 | 291,185 | |||||||||||
| Deferred revenues, net of current | - | 9,713 | |||||||||||
| Deferred tax liabilities, net | 157,404 | 157,945 | |||||||||||
| Other long-term liabilities | 67,782 | 68,015 | |||||||||||
| Total long-term liabilities | 2,403,930 | 2,417,888 | |||||||||||
| COMMITMENTS AND CONTINGENCIES | |||||||||||||
| SHAREHOLDERS' EQUITY: | |||||||||||||
| Ordinary shares, $0.0001 nominal value; 300,000,000 shares authorized; | |||||||||||||
| 166,974,870 and 164,785,083 shares issued at June 30, 2018 and | |||||||||||||
| December 31, 2017, respectively, and 166,590,504 and 164,400,717 shares | |||||||||||||
| outstanding at June 30, 2018 and December 31, 2017, respectively | 17 | 16 | |||||||||||
| Treasury stock, 384,366 ordinary shares at June 30, 2018 and December 31, 2017 | (4,585 | ) | (4,585 | ) | |||||||||
| Additional paid-in capital | 2,306,754 | 2,248,979 | |||||||||||
| Accumulated other comprehensive loss | (1,128 | ) | (983 | ) | |||||||||
| Accumulated deficit | (1,440,908 | ) | (1,252,329 | ) | |||||||||
| Total shareholders' equity | 860,150 | 991,098 | |||||||||||
| Total liabilities and shareholders' equity | $ | 3,989,725 | $ | 4,203,955 | |||||||||
| Horizon Pharma plc | ||||||||||||||||||||
| Condensed Consolidated Statements of Cash Flows (Unaudited) | ||||||||||||||||||||
| (in thousands) | ||||||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||||||
| 2018 | 2017 | 2018 | 2017 | |||||||||||||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||||||||||||||
| Net loss | $ | (32,836 | ) | $ | (209,536 | ) | $ | (190,164 | ) | $ | (300,106 | ) | ||||||||
| Adjustments to reconcile net loss to net cash provided by operating activities: | ||||||||||||||||||||
| Depreciation and amortization expense | 68,540 | 71,531 | 137,447 | 143,014 | ||||||||||||||||
| Equity-settled share-based compensation | 30,721 | 29,123 | 58,554 | 57,960 | ||||||||||||||||
| Royalty accretion | 14,758 | 12,735 | 29,475 | 25,694 | ||||||||||||||||
| Royalty liability remeasurement | - | - | (2,151 | ) | (2,944 | ) | ||||||||||||||
| Impairment of long-lived assets | - | 22,270 | 37,853 | 22,270 | ||||||||||||||||
| Amortization of debt discount and deferred financing costs | 5,690 | 5,206 | 11,185 | 10,629 | ||||||||||||||||
| Deferred income taxes | (3,433 | ) | (31,791 | ) | (1,753 | ) | (79,486 | ) | ||||||||||||
| Acquired in-process research & development expense | - | 148,609 | - | 148,609 | ||||||||||||||||
| Gain on divestiture | - | (2,635 | ) | - | (2,635 | ) | ||||||||||||||
| Loss on debt extinguishment | - | - | - | 533 | ||||||||||||||||
| Foreign exchange and other adjustments | 580 | (174 | ) | 459 | 613 | |||||||||||||||
| Changes in operating assets and liabilities: | ||||||||||||||||||||
| Accounts receivable | 678 | (6,209 | ) | 1,742 | (97,267 | ) | ||||||||||||||
| Inventories | (2,741 | ) | 30,686 | 11,549 | 67,736 | |||||||||||||||
| Prepaid expenses and other current assets | (11,934 | ) | 4,879 | (21,738 | ) | 2,434 | ||||||||||||||
| Accounts payable | (10,120 | ) | (6,255 | ) | (3,592 | ) | 29,823 | |||||||||||||
| Accrued trade discounts and rebates | 19,982 | 871 | (52,138 | ) | 116,950 | |||||||||||||||
| Accrued expenses and accrued royalties | (18,553 | ) | (36,876 | ) | (14,099 | ) | (86,235 | ) | ||||||||||||
| Deferred revenues | 1,817 | 1,002 | 333 | 384 | ||||||||||||||||
| Other non-current assets and liabilities | (1,361 | ) | 14,489 | (1,988 | ) | 14,755 | ||||||||||||||
| Net cash provided by operating activities | 61,788 | 47,925 | 974 | 72,731 | ||||||||||||||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||||||||||||||
| Payments for acquisitions, net of cash acquired | - | (167,850 | ) | - | (167,850 | ) | ||||||||||||||
| Proceeds from divestiture, net of cash divested | - | 69,072 | - | 69,072 | ||||||||||||||||
| Payment related to license agreement | - | - | (12,000 | ) | - | |||||||||||||||
| Purchases of property and equipment | (96 | ) | (1,207 | ) | (762 | ) | (2,627 | ) | ||||||||||||
| Net cash used in investing activities | (96 | ) | (99,985 | ) | (12,762 | ) | (101,405 | ) | ||||||||||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||||||||||||||
| Repayment of term loans | (25,598 | ) | (2,125 | ) | (27,722 | ) | (774,875 | ) | ||||||||||||
| Net proceeds from term loans | - | - | - | 847,768 | ||||||||||||||||
| Proceeds from the issuance of ordinary shares in connection with warrant exercises | - | 11 | - | 11 | ||||||||||||||||
| Proceeds from the issuance of ordinary shares through ESPP programs | 4,720 | 4,029 | 4,734 | 3,856 | ||||||||||||||||
| Proceeds from the issuance of ordinary shares in connection with stock option exercises | 2,727 | 753 | 3,672 | 1,297 | ||||||||||||||||
| Payment of employee withholding taxes relating to share-based awards | (5,668 | ) | (925 | ) | (9,185 | ) | (5,202 | ) | ||||||||||||
| Repurchase of ordinary shares | - | (992 | ) | - | (992 | ) | ||||||||||||||
| Net cash (used in) provided by financing activities | (23,819 | ) | 751 | (28,501 | ) | 71,863 | ||||||||||||||
| Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash | (1,988 | ) | 2,494 | (1,003 | ) | 2,196 | ||||||||||||||
| Net increase (decrease) in cash, cash equivalents and restricted cash | 35,885 | (48,815 | ) | (41,292 | ) | 45,385 | ||||||||||||||
| Cash, cash equivalents and restricted cash, beginning of the period(1) | 680,720 | 610,350 | 757,897 | 516,150 | ||||||||||||||||
| Cash, cash equivalents and restricted cash, end of the period(1) | $ | 716,605 | $ | 561,535 | $ | 716,605 | $ | 561,535 | ||||||||||||
|
(1) |
Amounts include restricted cash balance in accordance with ASU No. 2016-18. Cash and cash equivalents excluding restricted cash are shown on the balance sheet. |
|||||||||||||||||||
| Horizon Pharma plc | ||||||||||||||||||
|
Segment Operating Income – 2017 Historical Information (Unaudited) |
||||||||||||||||||
| (in millions) | ||||||||||||||||||
|
|
||||||||||||||||||
| Q1 17 | Q2 17 | Q3 17 | Q4 17 | FY17 | ||||||||||||||
| Segment Net Sales | ||||||||||||||||||
| Orphan & Rheumatology | $ | 155.2 | $ | 172.1 | $ | 175.6 | $ | 178.0 | $ | 680.9 | ||||||||
| Primary Care | 65.6 | 117.4 | 96.1 | 96.2 | 375.3 | |||||||||||||
| Segment Operating Income | ||||||||||||||||||
| Orphan & Rheumatology | $ | 49.7 | $ | 64.7 | $ | 65.5 | $ | 61.2 | $ | 241.1 | ||||||||
| Primary Care | 2.6 | 62.4 | 42.2 | 41.9 | 149.1 | |||||||||||||
| Horizon Pharma plc | ||||||||||
| Net Debt Reconciliation (Unaudited) | ||||||||||
| (in thousands) | ||||||||||
| As of | ||||||||||
| June 30, | December 31, | |||||||||
| 2018 | 2017 | |||||||||
| Long-term debt-current portion | $ | - | $ | 10,625 | ||||||
| Long-term debt, net of current | 1,562,013 | 1,576,646 | ||||||||
| Exchangeable notes, net | 323,105 | 314,384 | ||||||||
| Total Debt | 1,885,118 | 1,901,655 | ||||||||
| Debt discount | 97,737 | 108,054 | ||||||||
| Deferred financing fees | 10,171 | 11,041 | ||||||||
| Total Principal Amount Debt | 1,993,026 | 2,020,750 | ||||||||
| Less: cash and cash equivalents | 710,211 | 751,368 | ||||||||
| Net Debt | $ | 1,282,815 | $ | 1,269,382 | ||||||
| Horizon Pharma plc | |||||||||||||||||||
| GAAP to Non-GAAP Reconciliations | |||||||||||||||||||
| Net Income and Earnings Per Share (Unaudited) | |||||||||||||||||||
| (in thousands, except share and per share data) | |||||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||
| 2018 | 2017 | 2018 | 2017 | ||||||||||||||||
| GAAP net loss | $ | (32,836 | ) | $ | (209,536 | ) | $ | (190,164 | ) | $ | (300,106 | ) | |||||||
| Non-GAAP adjustments: | |||||||||||||||||||
| Acquisition/divestiture-related costs | 1,775 | 153,385 | 5,686 | 163,424 | |||||||||||||||
| Restructuring and realignment costs | 7,039 | 5,193 | 10,381 | 5,193 | |||||||||||||||
| Litigation settlements | 4,250 | - | 4,250 | - | |||||||||||||||
| Amortization, accretion and step-up: | |||||||||||||||||||
| Intangible amortization expense | 66,989 | 69,776 | 134,344 | 139,453 | |||||||||||||||
| Accretion of royalty liabilities | 14,797 | 12,735 | 29,515 | 25,694 | |||||||||||||||
| Amortization of debt discount and deferred financing costs | 5,691 | 5,206 | 11,187 | 10,629 | |||||||||||||||
| Inventory step-up expense | 53 | 33,895 | 17,129 | 74,490 | |||||||||||||||
| Impairment of long-lived assets | - | 22,270 | 37,853 | 22,270 | |||||||||||||||
| Remeasurement of royalties for medicines acquired through business combinations | - | - | (2,151 | ) | (2,944 | ) | |||||||||||||
| Share-based compensation | 30,721 | 27,768 | 58,554 | 56,237 | |||||||||||||||
| Depreciation | 1,551 | 1,755 | 3,104 | 3,561 | |||||||||||||||
| Gain on divestiture | - | (5,856 | ) | - | (5,856 | ) | |||||||||||||
| Charges relating to discontinuation of Friedreich's ataxia program | 272 | (3,103 | ) | 1,222 | (3,103 | ) | |||||||||||||
| Drug substance harmonization costs | 475 | 745 | 1,279 | 5,044 | |||||||||||||||
| Upfront and milestone payments related to license agreements | - | - | 90 | - | |||||||||||||||
| Fees related to term loan refinancings | 15 | (45 | ) | 42 | 4,098 | ||||||||||||||
| Loss on debt extinguishment | - | - | - | 533 | |||||||||||||||
| Royalties for medicines acquired through business combinations | (13,259 | ) | (11,622 | ) | (25,780 | ) | (22,939 | ) | |||||||||||
| Total of pre-tax non-GAAP adjustments | 120,369 | 312,102 | 286,705 | 475,784 | |||||||||||||||
| Income tax effect of pre-tax non-GAAP adjustments | (7,015 | ) | (34,272 | ) | 24,668 | (72,375 | ) | ||||||||||||
| Other non-GAAP income tax adjustments | - | - | (35,893 | ) | - | ||||||||||||||
| Total of non-GAAP adjustments | 113,354 | 277,830 | 275,480 | 403,409 | |||||||||||||||
| Non-GAAP Net Income | $ | 80,518 | $ | 68,294 | $ | 85,316 | $ | 103,303 | |||||||||||
| Non-GAAP Earnings Per Share: | |||||||||||||||||||
| Weighted average ordinary shares - Basic | 165,536,826 | 162,931,930 | 164,921,722 | 162,486,946 | |||||||||||||||
| Non-GAAP Earnings Per Share - Basic: | |||||||||||||||||||
| GAAP loss per share - Basic | $ | (0.20 | ) | $ | (1.29 | ) | $ | (1.15 | ) | $ | (1.85 | ) | |||||||
| Non-GAAP adjustments | 0.69 | 1.71 | 1.67 | 2.49 | |||||||||||||||
| Non-GAAP earnings per share - Basic | $ | 0.49 | $ | 0.42 | $ | 0.52 | $ | 0.64 | |||||||||||
| Weighted average ordinary shares - Diluted | |||||||||||||||||||
| Weighted average ordinary shares - Basic | 165,536,826 | 162,931,930 | 164,921,722 | 162,486,946 | |||||||||||||||
| Ordinary share equivalents | 3,820,913 | 2,033,141 | 3,678,249 | 2,499,409 | |||||||||||||||
| Weighted average shares - Diluted | 169,357,739 | 164,965,071 | 168,599,971 | 164,986,355 | |||||||||||||||
| Non-GAAP Earnings Per Share - Diluted | |||||||||||||||||||
| GAAP loss per share - Diluted | $ | (0.20 | ) | $ | (1.29 | ) | $ | (1.15 | ) | $ | (1.85 | ) | |||||||
| Non-GAAP adjustments | 0.69 | 1.71 | 1.67 | 2.49 | |||||||||||||||
| Diluted earnings per share effect of ordinary share equivalents | (0.01 | ) | (0.01 | ) | (0.01 | ) | (0.01 | ) | |||||||||||
| Non-GAAP earnings per share - Diluted | $ | 0.48 | $ | 0.41 | $ | 0.51 | $ | 0.63 | |||||||||||
| Horizon Pharma plc | |||||||||||||||||||
| GAAP to Non-GAAP Reconciliations | |||||||||||||||||||
|
EBITDA (Unaudited) |
|||||||||||||||||||
| (in thousands, except percentages) | |||||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||
| 2018 | 2017 | 2018 | 2017 | ||||||||||||||||
| GAAP net loss | $ | (32,836 | ) | $ | (209,536 | ) | $ | (190,164 | ) | $ | (300,106 | ) | |||||||
| Depreciation | 1,551 | 1,755 | 3,104 | 3,561 | |||||||||||||||
| Amortization, accretion and step-up: | |||||||||||||||||||
| Intangible amortization expense | 66,989 | 69,776 | 134,344 | 139,453 | |||||||||||||||
| Accretion of royalty liabilities | 14,797 | 12,735 | 29,515 | 25,694 | |||||||||||||||
| Amortization of deferred revenue | - | (207 | ) | - | (411 | ) | |||||||||||||
| Inventory step-up expense | 53 | 33,895 | 17,129 | 74,490 | |||||||||||||||
| Interest expense, net (including amortization of | |||||||||||||||||||
| debt discount and deferred financing costs) | 31,030 | 31,608 | 61,484 | 63,591 | |||||||||||||||
| Expense (benefit) for income taxes | 3,962 | (1,767 | ) | 3,596 | (49,320 | ) | |||||||||||||
| EBITDA | $ | 85,546 | $ | (61,741 | ) | $ | 59,008 | $ | (43,048 | ) | |||||||||
| Other non-GAAP adjustments: | |||||||||||||||||||
| Acquisition/divestiture-related costs | 1,775 | 153,385 | 5,686 | 163,424 | |||||||||||||||
| Restructuring and realignment costs | 7,039 | 5,193 | 10,381 | 5,193 | |||||||||||||||
| Litigation settlements | 4,250 | - | 4,250 | - | |||||||||||||||
| Impairment of long-lived assets | - | 22,270 | 37,853 | 22,270 | |||||||||||||||
| Remeasurement of royalties for medicines acquired through business combinations | - | - | (2,151 | ) | (2,944 | ) | |||||||||||||
| Share-based compensation | 30,721 | 27,768 | 58,554 | 56,237 | |||||||||||||||
| Charges relating to discontinuation of Friedreich's ataxia program | 272 | (3,103 | ) | 1,222 | (3,103 | ) | |||||||||||||
| Drug substance harmonization costs | 475 | 745 | 1,279 | 5,044 | |||||||||||||||
| Upfront and milestone payments related to license agreements | - | - | 90 | - | |||||||||||||||
| Fees related to term loan refinancings | 15 | (45 | ) | 42 | 4,098 | ||||||||||||||
| Loss on debt extinguishment | - | - | - | 533 | |||||||||||||||
| Gain on divestiture | - | (5,856 | ) | - | (5,856 | ) | |||||||||||||
| Royalties for medicines acquired through business combinations | (13,259 | ) | (11,622 | ) | (25,780 | ) | (22,939 | ) | |||||||||||
| Total of other non-GAAP adjustments | 31,288 | 188,735 | 91,426 | 221,957 | |||||||||||||||
| Adjusted EBITDA | $ | 116,834 | $ | 126,994 | $ | 150,434 | $ | 178,909 | |||||||||||
| Horizon Pharma plc | |||||||||||||||||||
| GAAP to Non-GAAP Reconciliations | |||||||||||||||||||
|
Operating Income (Unaudited) |
|||||||||||||||||||
| (in thousands, except percentages) | |||||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||
| 2018 | 2017 | 2018 | 2017 | ||||||||||||||||
| GAAP Operating Income (Loss) | $ | 1,814 | $ | (185,667 | ) | $ | (125,494 | ) | $ | (291,050 | ) | ||||||||
| Non-GAAP adjustments: | |||||||||||||||||||
| Acquisition/divestiture-related costs | 1,775 | 153,385 | 5,686 | 163,424 | |||||||||||||||
| Restructuring and realignment costs | 7,039 | 5,193 | 10,381 | 5,193 | |||||||||||||||
| Litigation settlements | 4,250 | - | 4,250 | - | |||||||||||||||
| Amortization, accretion and step-up: | |||||||||||||||||||
| Intangible amortization expense | 66,989 | 69,776 | 134,344 |
|
139,453 | ||||||||||||||
| Accretion of royalty liabilities | 14,797 | 12,735 | 29,515 | 25,694 | |||||||||||||||
| Inventory step-up expense | 53 | 33,895 | 17,129 | 74,490 | |||||||||||||||
| Impairment of long-lived assets | - | 22,270 | 37,853 | 22,270 | |||||||||||||||
| Remeasurement of royalties for medicines acquired through business combinations | - | - | (2,151 | ) | (2,944 | ) | |||||||||||||
| Share-based compensation | 30,721 | 27,768 | 58,554 | 56,237 | |||||||||||||||
| Depreciation | 1,551 | 1,755 | 3,104 | 3,561 | |||||||||||||||
| Charges relating to discontinuation of Friedreich's ataxia program | 272 | (3,103 | ) | 1,222 | (3,103 | ) | |||||||||||||
| Drug substance harmonization costs | 475 | 745 | 1,279 | 5,044 | |||||||||||||||
| Upfront and milestone payments related to license agreements | - | - | 90 | - | |||||||||||||||
| Fees related to term loan refinancings | 15 | (45 | ) | 42 | 4,098 | ||||||||||||||
| Royalties for medicines acquired through business combinations | (13,259 | ) | (11,622 | ) | (25,780 | ) | (22,939 | ) | |||||||||||
| Total of non-GAAP adjustments | 114,678 | 312,752 | 275,518 | 470,478 | |||||||||||||||
| Non-GAAP Operating Income | $ | 116,492 | $ | 127,085 | $ | 150,024 | $ | 179,428 | |||||||||||
| Orphan and Rheumatology Segment Operating Income | 70,609 | 64,662 | 113,713 | 114,386 | |||||||||||||||
| Primary Care Segment Operating Income | 45,883 | 62,423 | 36,311 | 65,042 | |||||||||||||||
| Total Segment Operating Income | $ | 116,492 | $ | 127,085 | $ | 150,024 | $ | 179,428 | |||||||||||
| Amortization of deferred revenue | - | (207 | ) | - | (411 | ) | |||||||||||||
| Foreign exchange (loss) gain | (5 | ) | 151 | (115 | ) | (108 | ) | ||||||||||||
| Other income, net | 347 | (35 | ) | 525 | - | ||||||||||||||
| Adjusted EBITDA | $ | 116,834 | $ | 126,994 | $ | 150,434 | $ | 178,909 | |||||||||||
| Horizon Pharma plc | |||||||||||||||||||
| GAAP to Non-GAAP Reconciliations | |||||||||||||||||||
| Gross Profit and Operating Cash Flow (Unaudited) | |||||||||||||||||||
| (in thousands, except percentages) | |||||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||
| 2018 | 2017 | 2018 | 2017 | ||||||||||||||||
| Non-GAAP Gross Profit: | |||||||||||||||||||
| GAAP gross profit | $ | 202,753 | $ | 159,357 | $ | 310,542 | $ | 241,100 | |||||||||||
| Non-GAAP gross profit adjustments: | |||||||||||||||||||
| Acquisition/divestiture-related costs | 33 | (48 | ) | 52 | 32 | ||||||||||||||
| Share-based compensation | 1,110 | 573 | 1,893 | 1,001 | |||||||||||||||
| Remeasurement of royalties for medicines acquired through business combinations | - | - | (2,151 | ) | (2,944 | ) | |||||||||||||
| Intangible amortization expense | 66,787 | 69,574 | 133,942 | 139,048 | |||||||||||||||
| Accretion of royalty liabilities | 14,797 | 12,735 | 29,515 | 25,694 | |||||||||||||||
| Inventory step-up expense | 53 | 33,895 | 17,129 | 74,490 | |||||||||||||||
| Depreciation | 176 | 183 | 353 | 366 | |||||||||||||||
| Charges relating to discontinuation of Friedreich's ataxia program | 185 | (3,103 | ) | 1,135 | (3,103 | ) | |||||||||||||
| Drug substance harmonization costs | 475 | 745 | 1,279 | 5,044 | |||||||||||||||
| Royalties for medicines acquired through business combinations | (13,259 | ) | (11,622 | ) | (25,780 | ) | (22,939 | ) | |||||||||||
| Total of Non-GAAP adjustments | 70,357 | 102,932 | 157,367 | 216,689 | |||||||||||||||
| Non-GAAP gross profit | $ | 273,110 | $ | 262,289 | $ | 467,909 | $ | 457,789 | |||||||||||
| GAAP gross profit % | 67.0 | % | 55.0 | % | 59.0 | % | 47.2 | % | |||||||||||
| Non-GAAP gross profit % | 90.2 | % | 90.6 | % | 88.8 | % | 89.7 | % | |||||||||||
| GAAP cash provided by operating activities | $ | 61,788 | $ | 47,925 | $ | 974 | $ | 72,731 | |||||||||||
| Cash payments for acquisition/divestiture-related costs | 1,597 | 12,620 | 5,555 | 33,012 | |||||||||||||||
| Cash payments for restructuring and realignment costs | 4,230 | 1,664 | 4,677 | 1,664 | |||||||||||||||
| Cash payments for litigation settlements | 1,500 | 16,250 | 1,500 | 32,500 | |||||||||||||||
| Cash payments for upfront and milestone payments related to license agreement | - | - | 275 | - | |||||||||||||||
| Cash payments drug substance harmonization costs | 5,960 | 5,006 | 5,960 | 5,006 | |||||||||||||||
| Cash payments for discontinuation of Friedreich's ataxia program | 108 | 2,519 | 3,507 | 3,001 | |||||||||||||||
| Cash payments relating to term loan refinancings | 13 | 455 | 31 | 3,767 | |||||||||||||||
| Non-GAAP operating cash flow | $ | 75,196 | $ | 86,439 | $ | 22,479 | $ | 151,681 | |||||||||||
| Horizon Pharma plc | |||||||||||||||||||
| GAAP to Non-GAAP Tax Rate Reconciliation (Unaudited) | |||||||||||||||||||
| (in millions, except percentages) | |||||||||||||||||||
| Q2 2018 | |||||||||||||||||||
| Pre-tax Net | Income Tax |
|
Net (Loss) | Diluted (Loss) | |||||||||||||||
| (Loss) Income | (Benefit) Expense |
Tax Rate |
Income | Earnings Per Share | |||||||||||||||
| As reported - GAAP | $ | (28.9 | ) | $ | 3.9 | (13.7 | )% | $ |
(32.8 |
) | $ | (0.20 | ) | ||||||
| Non-GAAP adjustments | 120.4 | 7.1 | 113.3 | ||||||||||||||||
| Non-GAAP | $ | 91.5 | $ | 11.0 | 12.0 | % | $ | 80.5 | $ | 0.48 | |||||||||
| Q2 2017 | |||||||||||||||||||
| Pre-tax Net |
Income Tax |
Net (Loss) | Diluted (Loss) | ||||||||||||||||
| (Loss) Income |
(Benefit) Expense |
Tax Rate | Income | Earnings Per Share | |||||||||||||||
| As reported - GAAP | $ | (211.3 | ) | $ | (1.8 | ) | 0.8 | % | $ | (209.5 | ) | $ | (1.29 | ) | |||||
| Non-GAAP adjustments | 312.1 | 34.3 | 277.8 | ||||||||||||||||
| Non-GAAP | $ | 100.8 | $ | 32.5 | 32.2 | % | $ | 68.3 | $ | 0.41 | |||||||||
| YTD 2018 | |||||||||||||||||||
| Pre-tax Net | Income Tax | Net (Loss) | Diluted (Loss) | ||||||||||||||||
| (Loss) Income | (Benefit) Expense | Tax Rate | Income | Earnings Per Share | |||||||||||||||
| As reported - GAAP | $ | (186.6 | ) | $ | 3.6 | (1.9 | )% | $ | (190.2 | ) | $ | (1.15 | ) | ||||||
| Non-GAAP adjustments | 286.7 | 11.2 | 275.5 | ||||||||||||||||
| Non-GAAP | $ | 100.1 | $ | 14.8 | 14.8 | % | $ | 85.3 | $ | 0.51 | |||||||||
| YTD 2017 | |||||||||||||||||||
| Pre-tax Net | Income Tax | Net (Loss) | Diluted (Loss) | ||||||||||||||||
| (Loss) Income | (Benefit) Expense | Tax Rate | Income | Earnings Per Share | |||||||||||||||
| As reported - GAAP | $ | (349.4 | ) | $ | (49.3 | ) | 14.1 | % | $ | (300.1 | ) | $ | (1.85 | ) | |||||
| Non-GAAP adjustments | 475.8 | 72.4 | 403.4 | ||||||||||||||||
| Non-GAAP | $ | 126.4 | $ | 23.1 | 18.2 | % | $ | 103.3 | $ | 0.63 | |||||||||
| Horizon Pharma plc | ||||||||||||||||||||||||||||||
| Certain Income Statement Line Items - Non-GAAP Adjusted | ||||||||||||||||||||||||||||||
| For the Three Months Ended June 30, 2018 | ||||||||||||||||||||||||||||||
| (Unaudited) | ||||||||||||||||||||||||||||||
|
(in thousands) |
||||||||||||||||||||||||||||||
| Income Tax | ||||||||||||||||||||||||||||||
| Research & | Selling, General | Interest | Benefit | |||||||||||||||||||||||||||
| COGS | Development | & Administrative | Expense | (Expense) | ||||||||||||||||||||||||||
| GAAP as reported | $ | (100,082 | ) | $ | (24,265 | ) | $ | (176,674 | ) | $ | (31,030 | ) | $ | (3,962 | ) | |||||||||||||||
| Non-GAAP Adjustments (in thousands): | ||||||||||||||||||||||||||||||
| Acquisition/divestiture-related costs(1) | 33 | 18 | 1,724 | - | - | |||||||||||||||||||||||||
| Restructuring and realignment costs(2) | - | 1,733 | 5,306 | - | - | |||||||||||||||||||||||||
| Litigation settlements(3) | - | - | 4,250 | - | - | |||||||||||||||||||||||||
| Amortization, accretion and step-up: | ||||||||||||||||||||||||||||||
| Intangible amortization expense(4) | 66,787 | - | 202 | - | - | |||||||||||||||||||||||||
| Accretion of royalty liability(5) | 14,797 | - | - | - | - | |||||||||||||||||||||||||
| Amortization of debt discount and deferred financing costs(6) | - | - | - | 5,691 | - | |||||||||||||||||||||||||
| Inventory step-up expense(7) | 53 | - | - | - | - | |||||||||||||||||||||||||
| Share-based compensation(10) | 1,110 | 2,209 | 27,402 | - | - | |||||||||||||||||||||||||
| Depreciation(11) | 176 | - | 1,375 | - | - | |||||||||||||||||||||||||
| Charges relating to discontinuation of Friedreich's ataxia program(12) | 185 | 87 | - | - | - | |||||||||||||||||||||||||
| Drug substance harmonization costs(13) | 475 | - | - | - | - | |||||||||||||||||||||||||
| Fees related to term loan refinancings(15) | - | - | 15 | - | - | |||||||||||||||||||||||||
| Royalties for medicines acquired through business combinations(16) | (13,259 | ) | - | - | - | - | ||||||||||||||||||||||||
| Income tax effect on pre-tax non-GAAP adjustments(17) | - | - | - | - | (7,015 | ) | ||||||||||||||||||||||||
| Total of non-GAAP adjustments | 70,357 | 4,047 | 40,274 | 5,691 | (7,015 | ) | ||||||||||||||||||||||||
| Non-GAAP | $ | (29,725 | ) | $ | (20,218 | ) | $ | (136,400 | ) | $ | (25,339 | ) | $ | (10,977 | ) | |||||||||||||||
| Horizon Pharma plc | ||||||||||||||||||||||||||||||
| Certain Income Statement Line Items - Non-GAAP Adjusted | ||||||||||||||||||||||||||||||
| For the Three Months Ended June 30, 2017 | ||||||||||||||||||||||||||||||
| (Unaudited) | ||||||||||||||||||||||||||||||
| (in thousands) | ||||||||||||||||||||||||||||||
| Research & | Selling, General | Impairment of | Interest | Gain on | Income Tax Benefit | |||||||||||||||||||||||||
| COGS | Development | & Administrative |
Long-Lived Assets |
Expense | Divestiture | (Expense) | ||||||||||||||||||||||||
| GAAP as reported | $ | (130,150 | ) | $ | (163,101 | ) | $ | (159,653 | ) | $ | (22,270 | ) | $ | (31,608 | ) | $ | 5,856 | $ | 1,767 | |||||||||||
| Non-GAAP Adjustments (in thousands): | ||||||||||||||||||||||||||||||
| Acquisition/divestiture-related costs(1) | (48 | ) | 148,080 | 5,353 | - | - | - | - | ||||||||||||||||||||||
| Restructuring and realignment costs(2) | - | - | 5,193 | - | - | - | - | |||||||||||||||||||||||
| Amortization, accretion and step-up: | ||||||||||||||||||||||||||||||
| Intangible amortization expense(4) | 69,574 | - | 202 | - | - | - | - | |||||||||||||||||||||||
| Accretion of royalty liability(5) | 12,735 | - | - | - | - | - | - | |||||||||||||||||||||||
| Amortization of debt discount and deferred financing costs(6) | - | - | - | - | 5,206 | - | - | |||||||||||||||||||||||
| Inventory step-up expense(7) | 33,895 | - | - | - | - | - | - | |||||||||||||||||||||||
| Impairment of long-lived assets(8) | - | - | - | 22,270 | - | - | - | |||||||||||||||||||||||
| Share-based compensation(10) | 573 | 2,313 | 24,882 | - | - | - | - | |||||||||||||||||||||||
| Depreciation(11) | 183 | - | 1,572 | - | - | - | - | |||||||||||||||||||||||
| Charges relating to discontinuation of Friedreich's ataxia program(12) | (3,103 | ) | - | - | - | - | - | - | ||||||||||||||||||||||
| Drug substance harmonization costs(13) | 745 | - | - | - | - | - | - | |||||||||||||||||||||||
| Fees related to term loan refinancings(15) | - | - | (45 | ) | - | - | - | - | ||||||||||||||||||||||
| Royalties for medicines acquired through business combinations(16) | (11,622 | ) | - | - | - | - | - | - | ||||||||||||||||||||||
| Gain on divestiture(20) | - | - | - | - | - | (5,856 | ) | - | ||||||||||||||||||||||
| Income tax effect on pre-tax non-GAAP adjustments(17) | - | - | - | - | - | - | (34,272 | ) | ||||||||||||||||||||||
| Total of non-GAAP adjustments | 102,932 | 150,393 | 37,157 | 22,270 | 5,206 | (5,856 | ) | (34,272 | ) | |||||||||||||||||||||
| Non-GAAP | $ | (27,218 | ) | $ | (12,708 | ) | $ | (122,496 | ) | $ | - | $ | (26,402 | ) | $ | - | $ | (32,505 | ) | |||||||||||
| Horizon Pharma plc | ||||||||||||||||||||||||||||||||||
| Certain Income Statement Line Items - Non-GAAP Adjusted | ||||||||||||||||||||||||||||||||||
| For the Six Months Ended June 30, 2018 | ||||||||||||||||||||||||||||||||||
| (Unaudited) | ||||||||||||||||||||||||||||||||||
|
(in thousands) |
||||||||||||||||||||||||||||||||||
| Income Tax | ||||||||||||||||||||||||||||||||||
| Research & | Selling, General | Impairment of | Interest | Benefit | ||||||||||||||||||||||||||||||
| COGS | Development | & Administrative |
Long-Lived Assets |
Expense | (Expense) | |||||||||||||||||||||||||||||
| GAAP as reported | $ | (216,174 | ) | $ | (41,910 | ) | $ | (356,273 | ) | $ | (37,853 | ) | $ | (61,484 | ) | $ | (3,596 | ) | ||||||||||||||||
| Non-GAAP Adjustments (in thousands): | ||||||||||||||||||||||||||||||||||
| Acquisition/divestiture-related costs(1) | 52 | (67 | ) | 5,701 | - | - | - | |||||||||||||||||||||||||||
| Restructuring and realignment costs(2) | - | 1,733 | 8,648 | - | - | - | ||||||||||||||||||||||||||||
| Litigation settlements(3) | - | - | 4,250 | - | - | - | ||||||||||||||||||||||||||||
| Amortization, accretion and step-up: | ||||||||||||||||||||||||||||||||||
| Intangible amortization expense(4) | 133,942 | - | 402 | - | - | - | ||||||||||||||||||||||||||||
| Accretion of royalty liability(5) | 29,515 | - | - | - | - | - | ||||||||||||||||||||||||||||
| Amortization of debt discount and deferred financing costs(6) | - | - | - | - | 11,187 | - | ||||||||||||||||||||||||||||
| Inventory step-up expense(7) | 17,129 | - | - | - | - | - | ||||||||||||||||||||||||||||
| Impairment of long-lived assets(8) | - | - | - | 37,853 | - | - | ||||||||||||||||||||||||||||
| Remeasurement of royalties for medicines acquired through business combinations(9) | (2,151 | ) | - | - | - | - | - | |||||||||||||||||||||||||||
| Share-based compensation(10) | 1,893 | 4,649 | 52,012 | - | - | - | ||||||||||||||||||||||||||||
| Depreciation(11) | 353 | - | 2,751 | - | - | - | ||||||||||||||||||||||||||||
| Charges relating to discontinuation of Friedreich's ataxia program(12) | 1,135 | 87 | - | - | - | - | ||||||||||||||||||||||||||||
| Drug substance harmonization costs(13) | 1,279 | - | - | - | - | - | ||||||||||||||||||||||||||||
| Upfront and milestone payments related to license agreements(14) | - | 90 | - | - | - | - | ||||||||||||||||||||||||||||
| Fees related to term loan refinancings(15) | - | - | 42 | - | - | - | ||||||||||||||||||||||||||||
| Royalties for medicines acquired through business combinations(16) | (25,780 | ) | - | - | - | - | - | |||||||||||||||||||||||||||
| Income tax effect on pre-tax non-GAAP adjustments(17) | - | - | - | - | - | 24,668 | ||||||||||||||||||||||||||||
| Other non-GAAP income tax adjustments(18) | - | - | - | - | - | (35,893 | ) | |||||||||||||||||||||||||||
| Total of non-GAAP adjustments | 157,367 | 6,492 | 73,806 | 37,853 | 11,187 | (11,225 | ) | |||||||||||||||||||||||||||
| Non-GAAP | $ | (58,807 | ) | $ | (35,418 | ) | $ | (282,467 | ) | $ | - | $ | (50,297 | ) | $ | (14,821 | ) | |||||||||||||||||
| Horizon Pharma plc | ||||||||||||||||||||||||||||||||||
| Certain Income Statement Line Items - Non-GAAP Adjusted | ||||||||||||||||||||||||||||||||||
| For the Six Months Ended June 30, 2017 | ||||||||||||||||||||||||||||||||||
| (Unaudited) | ||||||||||||||||||||||||||||||||||
|
(in thousands) |
||||||||||||||||||||||||||||||||||
| Income Tax | ||||||||||||||||||||||||||||||||||
| Research & | Selling, General | Impairment of | Interest | Gain on | Loss on Debt | Benefit | ||||||||||||||||||||||||||||
| COGS | Development | & Administrative |
Long-Lived Assets |
Expense | Divestiture | Extinguishment | (Expense) | |||||||||||||||||||||||||||
| GAAP as reported | $ | (269,266 | ) | $ | (176,162 | ) | $ | (333,718 | ) | $ | (22,270 | ) | $ | (63,591 | ) | $ | 5,856 | $ | (533 | ) | $ | 49,320 | ||||||||||||
| Non-GAAP Adjustments (in thousands): | ||||||||||||||||||||||||||||||||||
| Acquisition/divestiture-related costs(1) | 32 | 148,257 | 15,135 | - | - | - | - | - | ||||||||||||||||||||||||||
| Restructuring and realignment costs(2) | - | - | 5,193 | - | - | - | - | - | ||||||||||||||||||||||||||
| Amortization, accretion and step-up: | ||||||||||||||||||||||||||||||||||
| Intangible amortization expense(4) | 139,048 | - | 405 | - | - | - | - | - | ||||||||||||||||||||||||||
| Accretion of royalty liability(5) | 25,694 | - | - | - | - | - | - | - | ||||||||||||||||||||||||||
| Amortization of debt discount and deferred financing costs(6) | - | - | - | - | 10,629 | - | - | - | ||||||||||||||||||||||||||
| Inventory step-up expense(7) | 74,490 | - | - | - | - | - | - | - | ||||||||||||||||||||||||||
| Impairment of long lived assets(8) | - | - | - | 22,270 | - | - | - | - | ||||||||||||||||||||||||||
| Remeasurement of royalties for medicines acquired through business combinations(9) | (2,944 | ) | - | - | - | - | - | - | - | |||||||||||||||||||||||||
| Share-based compensation(10) | 1,001 | 4,362 | 50,874 | - | - | - | - | - | ||||||||||||||||||||||||||
| Depreciation(11) | 366 | - | 3,195 | - | - | - | - | - | ||||||||||||||||||||||||||
| Charges relating to discontinuation of Friedreich's ataxia program(12) | (3,103 | ) | - | - | - | - | - | - | - | |||||||||||||||||||||||||
| Drug substance harmonization costs(13) | 5,044 | - | - | - | - | - | - | - | ||||||||||||||||||||||||||
| Fees related to term loan refinancing(15) | - | - | 4,098 | - | - | - | - | - | ||||||||||||||||||||||||||
| Royalties for medicines acquired through business combinations(16) | (22,939 | ) | - | - | - | - | - | - | - | |||||||||||||||||||||||||
| Loss on debt extinguishment(19) | - | - | - | - | - | - | 533 | - | ||||||||||||||||||||||||||
| Gain on divestiture(20) | - | - | - | - | - | (5,856 | ) | - | - | |||||||||||||||||||||||||
| Income tax effect on pre-tax non-GAAP adjustments(17) | - | - | - | - | - | - | - | (72,375 | ) | |||||||||||||||||||||||||
| Total of non-GAAP adjustments | 216,689 | 152,619 | 78,900 | 22,270 | 10,629 | (5,856 | ) | 533 | (72,375 | ) | ||||||||||||||||||||||||
| Non-GAAP | $ | (52,577 | ) | $ | (23,543 | ) | $ | (254,818 | ) | $ | - | $ | (52,962 | ) | $ | - | $ | - | $ | (23,055 | ) | |||||||||||||
|
NOTES FOR CERTAIN INCOME STATEMENT LINE ITEMS - NON-GAAP |
||
| (1) | Expenses, including legal and consulting fees, incurred in connection with the Company’s acquisitions and divestitures. | |
| (2) | Represents expenses, including severance costs and consulting fees, related to the restructuring and realignment activities. | |
| (3) | During the three and six months ended June 30, 2018, the Company recorded $4.3 million of expense for litigation settlements related to RAVICTI and PENNSAID 2%. | |
| (4) | Intangible amortization expenses are associated with the Company’s intellectual property rights, developed technology and customer relationships related to ACTIMMUNE, BUPHENYL, KRYSTEXXA, LODOTRA, MIGERGOT, PENNSAID 2%, PROCYSBI, RAVICTI, RAYOS and VIMOVO. | |
| (5) | Represents accretion expense associated with ACTIMMUNE, BUPHENYL, KRYSTEXXA, MIGERGOT, PROCYSBI, QUINSAIR, RAVICTI and VIMOVO contingent royalty liabilities. | |
| (6) | Represents amortization of debt discount and deferred financing costs associated with the Company's debt. | |
| (7) | During the three and six months ended June 30, 2018, the Company recognized in cost of goods sold nil and $17.1 million, respectively, for inventory step-up expense primarily related to KRYSTEXXA inventory sold. | |
| During the three and six months ended June 30, 2017, the Company recognized in cost of goods sold $19.3 million and $33.7 million, respectively, for inventory step-up expense related to KRYSTEXXA inventory sold and $14.6 million and $40.8 million, respectively, for inventory step-up expense related to PROCYSBI and QUINSAIR inventory sold. | ||
| (8) | During the six months ended June 30, 2018, the Company recorded an impairment of $37.9 million to write off the book value of developed technology related to PROCYSBI in Canada and Latin America due to lower than anticipated future net sales. | |
| Impairment of long-lived assets during the three and six months ended June 30, 2017 of $22.3 million relates to an impairment recorded following payment to Boehringer Ingelheim International for the acquisition of certain rights to interferon gamma-1b. This was presented in the “charges relating to the discontinuation of the Friedreich’s ataxia program” line item in the reconciliation of GAAP to non-GAAP measures during the year ended December 31, 2017. | ||
| (9) | At the time of the Company's acquisition of the rights to ACTIMMUNE, BUPHENYL, KRYSTEXXA, MIGERGOT, PROCYSBI, RAVICTI and VIMOVO, the Company estimated the fair value of contingent royalties payable to third parties using an income approach under the discounted cash flow method, which included revenue projections and other assumptions the Company made to determine the fair value. If the Company significantly overperforms or underperforms against its original revenue projections or it becomes necessary to make changes to assumptions as a result of a triggering event, the Company is required to reassess the fair value of the contingent royalties payable. Any subsequent adjustment to fair value is recorded in the period such adjustment is made as either an increase or decrease to royalties payable, with a corresponding increase or decrease in cost of goods sold, in accordance with established accounting policies. The Company recorded net decreases of $2.2 million and $2.9 million to cost of goods sold to adjust the amount of the contingent royalty liabilities relating to PROCYSBI during the first quarter of 2018, and to KRYSTEXXA and VIMOVO during the first quarter of 2017, respectively. | |
| (10) | Represents share-based compensation expense associated with the Company's stock option, restricted stock unit and performance stock unit grants to its employees and non-employees, its previous cash-settled long-term incentive plan and its employee stock purchase plan. | |
| (11) | Represents depreciation expense related to the Company’s property, equipment, software and leasehold improvements. | |
| (12) | Charges relating to discontinuation of the Friedreich’s ataxia program include a $1.1 million increase and $3.1 million reduction during the six months ended June 30, 2018 and 2017, respectively, in cost of goods sold relating to the purchase of additional units of ACTIMMUNE. | |
| (13) | During the year ended December 31, 2016, the Company committed to spend $14.9 million related to the harmonization of the manufacturing processes for ACTIMMUNE and IMUKIN drug substance. During the three and six months ended June 30, 2018, the Company incurred costs of $0.5 million and $1.3 million, respectively, related to these activities that qualify for exclusion in the Company’s non-GAAP financial measures under its non-GAAP cost policy. | |
| (14) | Represents upfront and milestone payments related to license agreements. | |
| (15) | Represents arrangement and other fees relating to the refinancing of the Company’s term loans. | |
| (16) | Royalties of $13.3 million and $25.8 million were incurred during the three and six months ended June 30, 2018, respectively, based on the periods’ net sales for ACTIMMUNE, BUPHENYL, KRYSTEXXA, MIGERGOT, PROCYSBI, QUINSAIR, RAVICTI and VIMOVO. | |
| (17) | Income tax adjustments on pre-tax non-GAAP adjustments represent the estimated income tax impact of each pre-tax non-GAAP adjustment based on the statutory income tax rate of the applicable jurisdictions for each non-GAAP adjustment. | |
| (18) | Other non-GAAP income tax adjustments during the six months ended June 30, 2018 reflect a measurement period adjustment relating to Notice 2018-28 that was issued by the U.S. Treasury Department and the U.S. Internal Revenue Service in April 2018 (“the notice”). In accordance with the measurement period provisions under SAB 118 and the guidance in the notice the Company reinstated the deferred tax asset related to its U.S. interest expense carry forwards under Section 163(j) based on the new U.S. federal tax rate of 21 percent. The impact of the deferred tax asset reinstatement in accordance with SAB 118 was a $35.9 million increase to the Company’s benefit for income taxes and a corresponding decrease to the U.S. group net deferred tax liability position. | |
| (19) | During the six months ended June 30, 2017, the Company recorded a loss on debt extinguishment of $0.5 million which comprised a write-off of $0.4 million in debt discount and deferred financing costs and an early redemption payment of $0.1 million. | |
| (20) | On June 23, 2017, the Company completed the divestiture of a European subsidiary that owns the marketing rights to PROCYSBI and QUINSAIR in Europe, the Middle East and Africa to Chiesi Farmaceutici S.p.A. In connection with this divestiture, the Company recorded a gain of $5.9 million in the three and six months ended June 30, 2017. | |